WEIGHT LOSS SPECIALIST – DHA LAHORE
Lanissa is a Tirzepatide-based injection for weight management – prescribed by specialist endocrinologist Dr. Rizwan Niazi in DHA Lahore.
لانیسا (Tirzepatide) ایک ہفتہ وار انجیکشن ہے جو بھوک کو کم کرتا ہے اور وزن میں مستقل کمی لاتا ہے۔ ڈاکٹر رضوان نیازی مکمل طبی معائنے کے بعد اسے تجویز کرتے ہیں۔
Lanissa is a brand formulation containing Tirzepatide – the same dual GLP-1 and GIP receptor agonist found in Mounjaro. It is a once-weekly injection prescribed for medically supervised weight management in patients who meet clinical criteria.
As with all Tirzepatide-based injections, Lanissa reduces appetite, slows digestion, and improves insulin sensitivity – delivering significant weight loss when combined with a structured medical plan under specialist supervision.
ⓘ Lanissa is a prescription injection. Availability is subject to current stock and regulatory status at time of consultation.
Lanissa contains Tirzepatide which activates both GLP-1 and GIP receptors – producing powerful appetite reduction and metabolic improvement.
Activates two hormone receptors simultaneously, producing a greater reduction in appetite and calorie intake than single-receptor injections.
Once-weekly subcutaneous injection makes adherence straightforward for most patients over the full treatment period.
Beyond weight loss: Tirzepatide improves insulin sensitivity, reduces HbA1c, and supports overall metabolic health.
Lanissa and Mounjaro both contain Tirzepatide. The key difference is branding and formulation source.
ⓘ Suitability and availability are determined at consultation. Dr. Rizwan will advise which formulation is most appropriate.
Lanissa contains Tirzepatide, which has been extensively studied in clinical trials. Specialist assessment is required before use.
Nausea, vomiting, diarrhoea, and reduced appetite are the most common – consistent with all Tirzepatide-based treatments. Most improve over time.
Not suitable for patients with thyroid cancer history, MEN2, pancreatitis, or certain other conditions. A full review is mandatory before prescribing.
When correctly assessed, prescribed, and monitored by Dr. Rizwan Niazi, Lanissa is safe for medically suitable patients.
Book a consultation with Dr. Rizwan Niazi for a full evaluation and personalised prescription plan.
Dr. Rizwan also prescribes the following injections based on individual patient assessment.
ⓘ All injections are prescribed based on individual assessment under proper medical supervision.
Lanissa must be prescribed and monitored by a qualified specialist. The right dose, proper titration, and regular follow-up are all essential for safe, effective results.
BMI, medical history, current medications, and metabolic markers are reviewed before Lanissa is prescribed.
Monthly reviews track your progress, allow dose adjustments, and ensure safe outcomes throughout treatment.
Blood tests confirm suitability and track your metabolic response during the course of treatment.
Lanissa, Mounjaro, Wegovy, Saxenda – each suits a different medical profile. Dr. Rizwan Niazi will recommend the safest, most effective option after a full evaluation.
Lanissa is an injectable weight loss medication containing Tirzepatide – a dual GLP-1 and GIP receptor agonist. It works by reducing appetite, slowing digestion, and improving insulin sensitivity.
Both Lanissa and Mounjaro contain the same active ingredient: Tirzepatide. They work through the same mechanism. The difference is in brand and formulation source. Dr. Rizwan will advise which is appropriate and available for your case.
Lanissa is available in Pakistan as a prescription medication. Availability may vary by stock. Dr. Rizwan Niazi prescribes it following full clinical assessment in DHA Lahore.
Lanissa is a once-weekly subcutaneous injection. The starting dose is low and gradually increased based on tolerance and response – consistent with other Tirzepatide protocols.
The most common side effects are nausea, vomiting, diarrhoea, and reduced appetite – consistent with all Tirzepatide-based treatments. These typically improve after the initial weeks of dose titration.
No. Lanissa is a prescription-only medication. A full clinical assessment is required before any injection is prescribed. Self-administration is unsafe and strongly discouraged.